FDA Expands TREMFYA Label to Include Joint Damage Data in Psoriatic Arthritis
HORSHAM, PA — The U.S. Food and Drug Administration has approved a label expansion for Johnson & Johnson’s (NYSE: JNJ) TREMFYA, allowing the company to market clinical evidence showing the …
FDA Expands TREMFYA Label to Include Joint Damage Data in Psoriatic Arthritis Read More